CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) and Keros Therapeutics (NASDAQ:KROS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Profitability
This table compares CAMP4 Therapeutics and Keros Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CAMP4 Therapeutics | -2,276.33% | -182.39% | -74.87% |
| Keros Therapeutics | -256.60% | -21.85% | -19.83% |
Insider & Institutional Ownership
71.6% of Keros Therapeutics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares CAMP4 Therapeutics and Keros Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CAMP4 Therapeutics | $3.50 million | 71.71 | -$80.40 million | ($2.14) | -1.87 |
| Keros Therapeutics | $244.06 million | 0.91 | $87.01 million | ($2.82) | -4.01 |
Keros Therapeutics has higher revenue and earnings than CAMP4 Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for CAMP4 Therapeutics and Keros Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CAMP4 Therapeutics | 1 | 1 | 8 | 1 | 2.82 |
| Keros Therapeutics | 1 | 2 | 3 | 1 | 2.57 |
CAMP4 Therapeutics presently has a consensus target price of $10.44, suggesting a potential upside of 161.11%. Keros Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 76.83%. Given CAMP4 Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe CAMP4 Therapeutics is more favorable than Keros Therapeutics.
Risk and Volatility
CAMP4 Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Summary
Keros Therapeutics beats CAMP4 Therapeutics on 7 of the 13 factors compared between the two stocks.
About CAMP4 Therapeutics
CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes.
About Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-?) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions.
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
